Loading stock…

Pro Medicus Limited (PME) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Pro Medicus Limited

PMEMarket cap $12BPrice $111.5

Country🇦🇺Australia

SectorHealthcare

IndustryHealthcare Tech

Sells cloud-based medical imaging software that lets radiologists read X-rays and MRIs faster and from anywhere. Its Visage platform powers scans for major US hospital systems, and Pro Medicus holds a near-perfect track record of contract renewals.

In Bastion Portfolios?

52W Return-40%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+30%10

Revenue Forecast

Rev CAGR (1y)+31%9

Rev CAGR (3y)+25%9

Rev CAGR (5y)+20%9

Earnings Forecast

EPS Growth Y+1-27%2

EPS Growth Y+2+27%8

EPS Growth Y+3+21%8

Quality

100

Margins

EBIT Margin75%10

Net Income Margin101%10

Free Cash Flow Margin49%10

Debt

Net Debt/EBITDA-1.310

Efficiency

ROE75%10

ROA56%10

Earnings Stability88

GEAR+VERY STRONG89

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)861

P/E Ratio (Forward 3y)571

P/BV36.61

EV Multiples

EV/EBITDA Fwd601

EV/EBIT Fwd621

Yield

Free Cash Flow Yield0.8%3

Dividend Yieldna–

Momentum

Short term

1 month return-6%4

3 month return-25%1

YTD return-28%2

Mid term

Price vs 52wHigh51%1

1 year return-47%1

Long term

3 year return+93%7

5 year return+206%9

Risk Shield

Price Risk

Beta0.86

Volatility55%3

Free Cash Flow

Free Cash Flow Margin49%10

Free Cash Flow Yield0.8%3

Quality

ROCE46%10

Earnings Stability88

Net Debt/EBITDA-1.310

02Growth

Is it actually growing, and how fast?

PMEPro Medicus

Revenue FY26$181M

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+30%10

Revenue, next 1Y+31%9

Revenue, next 3Y, CAGR+25%9

Revenue, next 5Y, CAGR+20%9

EARNINGS FORECAST▾SCORE

EPS growth, FY27E-27%2

EPS growth, FY28E+27%8

EPS growth, FY29E+21%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 30%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 25%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 20%/yr over five years.9/10

WATCH

Revenue grew 30%/yr over the last 3 years; forecasts see it cooling to 25%/yr.

Earnings are set to grow in step with sales (EPS about 21%/yr vs revenue 25%/yr). One year dips: EPS falls 27% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

PMEPro Medicus

Total return Current2710%

Price return Current2626%

MOMENTUM RATING↗

WEAK19 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return-25%1

YTD return-28%2

MID & LONG-TERM▾SCORE

% of 52-week high51%1

1-year return-47%1

3-year return+93%7

5-year return+206%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +93% over three years and +206% over five, ahead of 70% of the market.

WATCH

Returns sit at the market level over the past month (-6%).

WEAKNESSES

It's down 47% over the past year, now 49% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-25%) and so far this year (-28%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Pro Medicus. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

PMEPro Medicus

Revenue FY26$181M

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+30%10

Revenue, next 1Y+31%9

Revenue, next 3Y, CAGR+25%9

Revenue, next 5Y, CAGR+20%9

EARNINGS FORECAST▾SCORE

EPS growth, FY27E-27%2

EPS growth, FY28E+27%8

EPS growth, FY29E+21%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 30%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 25%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 20%/yr over five years.9/10

WATCH

Revenue grew 30%/yr over the last 3 years; forecasts see it cooling to 25%/yr.

Earnings are set to grow in step with sales (EPS about 21%/yr vs revenue 25%/yr). One year dips: EPS falls 27% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

PMEPro Medicus

Total return Current2710%

Price return Current2626%

MOMENTUM RATING↗

WEAK19 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return-25%1

YTD return-28%2

MID & LONG-TERM▾SCORE

% of 52-week high51%1

1-year return-47%1

3-year return+93%7

5-year return+206%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +93% over three years and +206% over five, ahead of 70% of the market.

WATCH

Returns sit at the market level over the past month (-6%).

WEAKNESSES

It's down 47% over the past year, now 49% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-25%) and so far this year (-28%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on Pro Medicus. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community